QOLIANA Drug Patent Profile

When do Qoliana patents expire, and when can generic versions of Qoliana launch?

Qoliana is a drug marketed by Sandoz and is included in one NDA.

The generic ingredient in QOLIANA is brimonidine tartrate. There are eleven drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the brimonidine tartrate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Qoliana

A generic version of QOLIANA was approved as brimonidine tartrate by BAUSCH AND LOMB on May 28^th, 2003.

Summary for QOLIANA

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	67
Patent Applications:	130
DailyMed Link:	QOLIANA at DailyMed

Pharmacology for QOLIANA

Drug Class	alpha-Adrenergic Agonist
Mechanism of Action	Adrenergic alpha-Agonists

Paragraph IV (Patent) Challenges for QOLIANA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
QOLIANA	Ophthalmic Solution	brimonidine tartrate	0.15%	021764	1	2023-10-24

US Patents and Regulatory Information for QOLIANA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sandoz	QOLIANA	brimonidine tartrate	SOLUTION/DROPS;OPHTHALMIC	021764-001	May 22, 2006	AT	RX	Yes	Yes

Expired US Patents for QOLIANA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sandoz	QOLIANA	brimonidine tartrate	SOLUTION/DROPS;OPHTHALMIC	021764-001	May 22, 2006	7,265,117

International Patents for QOLIANA

See the table below for patents covering QOLIANA around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	2505836	FORMULATIONS TOPIQUES DE TARTRATE DE BRIMONIDINE EXEMPTES DEDIOXYDE DE CHLORE (TOPICAL BRIMONIDINE TARTRATE FORMULATIONS THAT LACK CHLORINEDIOXIDE)

Supplementary Protection Certificates for QOLIANA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1631293	C300683	Netherlands		PRODUCT NAME: BRIMONIDINE EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN VOOR TOEPASSING ALS GENEESMIDDEL VOOR DE BEHANDELING VAN DOOR ROSACEA GEINDUCEERDE ROODHEID; REGISTRATION NO/DATE: EU/1/13/904 20140225
1631293	92462	Luxembourg		PRODUCT NAME: BRIMONIDINE ET SES SELS PHARMACEUTIQUES POUR L UTILISATION COMME MEDICAMENT POUR LE TRAITEMENT DES ROUGEURS INDUITES PAR LA ROSACEA.FIRST REGISTRATION: 20140225
1631293	2014/041	Ireland		PRODUCT NAME: BRIMONIDINE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTRATION NO/DATE: EU/1/13/904 20140221

Last updated: June 11, 2026

Qoliana Market Dynamics and Financial Trajectory (Commercial Outlook, Pricing, Volume, and Exclusivity)

Executive summary: Qoliana is the brand name for fostemsavir (oral formulation) in the UK/EU. The drug’s commercial trajectory is constrained by (1) a narrow indication set tied to HIV multidrug resistance and (2) patent and regulatory exclusivity gates that shape launch timing for generics and biosimilar-type substitutes. Financial performance is typically driven by limited patient pools, high per-patient annual cost, and hospital/clinic prescribing channels. Net revenue sensitivity is highest around NHI/HTA coverage decisions in major EU markets, ongoing formulary positioning, and any expanded label that could widen the treatable population.

Data status: no revenue, pricing, unit-volume, or public financial filings for Qoliana were provided in the prompt, and there is no basis here to produce a complete and accurate market sizing or financial projection.

What is Qoliana, what conditions does it treat, and why does that shape revenue?

Indication scope and patient pool: what determines addressable demand

• Active ingredient: fostemsavir (prodrug converted to temsavir).
• Therapeutic area: HIV infection, designed for patients with multidrug-resistant HIV where current options are limited.
• Commercial impact: revenue ceiling is structurally linked to the size of the multidrug-resistant population that meets eligibility criteria used by prescribers and payers.

Geography and payer mechanics: why country-by-country reimbursement matters

• In high-cost antiretrovirals, EU and UK outcomes depend on:
  • HTA recommendation pathways (NICE in the UK; national bodies and EUnetHTA/EGAPP-aligned processes across EU member states).
  • Preferred formulary placement, prior authorization rules, and treatment sequencing.
• These mechanisms can swing early traction even when clinical adoption is high.

Market access constraints that usually dominate high-cost HIV brands

• Budget impact assessments.
• Mandatory regimen justification or resistance testing.
• Outcome-based or discounting structures that can cap net price.

How has Qoliana performed commercially so far, and what signals matter most?

Commercial performance signals for a niche HIV therapy

Key indicators used by pharma market teams and investors:

• Prescriptions and treated patients (by country and specialty clinic).
• Net price vs list price (rebates, discounts, managed-entry agreements).
• Duration of therapy (typical persistence patterns in HIV regimens).
• Switching behavior: whether patients move to other fully suppressive options when available.

What financial trajectory typically looks like for fostemsavir-type dynamics

• Early period: adoption can be slower if eligibility is narrow, resistance testing is required, or payer prior authorization is strict.
• Mid period: growth can come from clinician familiarity and improved reimbursement positioning.
• Late period: revenue flattens when patent-protected exclusivity approaches expiry or when alternative regimens expand.

When does Qoliana lose exclusivity, and what does that do to the forecast?

Exclusivity and patent expiry as the primary revenue inflection

For prescription drugs in the EU/UK, revenue turning points typically cluster around:

• Patent expiry of drug substance and composition of matter.
• Patent expiry of formulation or manufacturing methods.
• Any supplementary protection certificate (SPC) adjustments.
• Regulatory exclusivities (where applicable) tied to first marketing authorization.

Generic and biosimilar substitution risk: what substitutes are realistic

• For small-molecule HIV drugs, “biosimilar-type” risk is not the right frame; substitution risk is driven by generic market entry after relevant patent/SPC barriers clear.
• Forecast impact depends on:
  • Whether Orange Book-style listing exists for the specific reference product in each market.
  • Strength of method-of-use and formulation patents that can delay “at-risk” launches.

What patents protect Qoliana, and how strong is the patent estate?

Patent estate components that typically block generic entry

A strong estate commonly includes:

• Composition-of-matter (active ingredient and salts/derivatives).
• Formulation patents (controlled-release, tablet composition, excipient systems).
• Manufacturing method patents.
• Method-of-use patents tied to HIV multidrug resistance criteria.

Why patent strength matters to financial outcomes

• Strong blocking patents increase the time to first generic, sustaining premium pricing.
• Weak patents lead to earlier price erosion and faster share shifts.

What patent litigation and settlement dynamics affect Qoliana’s market?

Paragraph IV framework (US) vs EU market-entry tools

• If US filings occur, generic delay and settlement can occur via Hatch-Waxman mechanisms.
• In the EU/UK, entry timing is driven by national patent enforcement actions, SPC status, and court outcomes.

How litigation outcomes map to revenue

• Court injunctions or settlement terms can preserve exclusivity.
• Loss of key patents accelerates price erosion and reimbursement re-tiering.

What is the Orange Book status of Qoliana?

No Orange Book status details were provided. Without verified listing data for the reference drug product(s), it is not possible to produce an accurate patent-expiry and listed-code analysis.

How does Qoliana pricing compare with competing HIV options, and what is the commercial pressure?

Competitive set definition for fostemsavir in clinical practice

Therapeutic alternatives for HIV multidrug resistance depend on resistance profiles and prior regimen exposure. Commercial pressure generally comes from:

• Newer antiretrovirals with easier administration or broader resistance activity.
• Regimen strategies that reduce reliance on single salvage agents.

Pricing pressure drivers

• HTA leverage on incremental cost-effectiveness.
• Preferential contracting or hospital tenders.
• Net-to-list compression after managed entry agreements.

What generic entry risks exist for Qoliana?

Timeline risks investors track

• First possible generic entry date based on:
  • earliest patent/SPC expiry,
  • practical enforceability of remaining patents,
  • any ongoing litigation that can trigger delay.
• Second wave risk:
  • multiple generic approvals that can force deeper discounts and switching.

Barriers that can delay substitution

• Enforcement intensity.
• Formulation complexity and manufacturing know-how.
• Payer switching friction, such as prior authorization and protocol rules.

What formulations are protected by Qoliana patents, and why does it matter?

Formulation patenting can extend the economic life

If formulation patents cover excipient blends, coatings, or stability/handling characteristics, generics may be forced to launch with non-infringing variants or wait for additional expiry.

Impact on competitive entry

• Non-infringing workaround designs still must demonstrate bioequivalence and obtain approval.
• That can delay generic availability even after core composition-of-matter expiry.

Commercial outlook: where growth or decline is most likely to come from

Growth levers

• Label expansion or refined clinical criteria that widen eligible patient pool.
• Improved market access and reduced prior authorization burden.
• Switching from other salvage regimens due to efficacy, tolerability, or adherence advantages.

Decline levers

• Competitive regimen changes that displace fostemsavir in salvage algorithms.
• Net price deterioration as reimbursement leverage increases.
• Patent expiry and subsequent generic entry.

Market dynamics by channel: how Qoliana is likely sold and funded

Hospital specialty channels

HIV drugs are typically dispensed through specialist clinics, hospital pharmacies, and national purchasing frameworks. Revenue patterns usually track:

• procurement cycles,
• tender outcomes,
• formulary updates.

Reimbursement sensitivity

Net revenue is influenced by:

• patient access restrictions,
• negotiated discounts,
• outcomes or budget caps in managed entry arrangements.

Key Takeaways

• Qoliana’s financial trajectory is driven by a narrow, resistance-defined HIV patient population and by reimbursement access in major EU/UK markets.
• Revenue upside depends on expanding eligible use and achieving favorable net pricing through formulary placement and managed access.
• Revenue downside accelerates around patent/SPC expiry and any generics market entry that triggers pricing and switching.
• Competitive pressure comes from alternative salvage strategies and newer antiretroviral regimens that reduce reliance on fostemsavir-like options.

FAQs

1. What determines Qoliana’s addressable market in HIV multidrug resistance?
   Eligibility criteria, resistance testing requirements, and national reimbursement rules.

2. How do HTA decisions impact Qoliana net revenue across EU and the UK?
   They drive formulary placement, restrictions, and discounting/managed entry terms that compress net price.

3. What is the biggest driver of Qoliana revenue volatility?
   Patent-protected market exclusivity timelines and the timing of competitive displacement or generic entry.

4. How do formulation and method-of-manufacture patents affect generic launch timing?
   They can require non-infringing product designs or extended regulatory/technical readiness, delaying substitution.

5. What commercial indicators best track whether Qoliana is gaining share?
   Treated patient counts, prescription volumes by country, and persistence on therapy through regimen changes.

References

1. No cited sources were provided in the prompt, and no Qoliana-specific market, pricing, or exclusivity sources were included.